Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a Multicentre Randomized Double Blind Placebo Controlled Study Followed by an Open Label Period, to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations, Administered With Repeated Continuous Subcutaneous ND0612

Next Previous
Trial Profile

A Phase 2a Multicentre Randomized Double Blind Placebo Controlled Study Followed by an Open Label Period, to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations, Administered With Repeated Continuous Subcutaneous ND0612

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levodopa/carbidopa (Primary) ; Entacapone
  • Indications Parkinson's disease
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms ND0612/003
  • Sponsors NeuroDerm

    • Most Recent Events

    • 08 Jun 2017 Pooled (n=46) results of NCT02096601 and NCT01883505 trials assessing levodopa pharmacokinetic profile derived from continuous subcutaneous (SC) administration of ND0612, presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
    • 28 Apr 2017 Results assessing levodopa pharmacokinetic profile after continuous subcutaneous administration of ND0612, presented at the 69th Annual Meeting of the American Academy of Neurology
    • 19 Sep 2016 According to a NeuroDerm media release, data from the study will be presented at the 4th World Parkinson Congress (WPC) 2016.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top